Abstracts Archive - Page 2343 of 2425 - ACR Meeting Abstracts

Abstract Number: 1185 • 2012 ACR/ARHP Annual Meeting
Regulatory Role of 1, 25 Dihydroxyvitamin D3 in the Pathogenesis of Autoimmune Arthritis
Siba P. Raychaudhuri¹, Ananya Datta Mitra², Anupam Mitra¹, Christine Abria² and Smriti K. Raychaudhuri², ¹Rheumatology, VA Sacramento Medical Center/UC Davis School of Medicine, Mather, CA, ²Rheumatology, VA Sacramento Medical Center, Mather, CA
Background/Purpose: Fibroblast like synoviocytes (FLS) and T lymphocytes are considered as major effector cells in the pathogenesis of autoimmune arthritis (AA) such as rheumatoid arthritis…
Abstract Number: 1186 • 2012 ACR/ARHP Annual Meeting
A Single Nucleotide Polymorphism of Tumor Necrosis Factor Receptor-Associated Factor 1 Predicts Clinical Response to Anti-Tumor Necrosis Factor Treatments in Japanese Patients with Rheumatoid Arthritis
Tetsuya Nishimoto¹, Noriyuki Seta², Ryusuke Anan², Tatsuya Yamamoto², Yuko Kaneko³, Masataka Kuwana⁴ and Tsutomu Takeuchi⁵, ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Internal Medicine, Keio university, Tokyo, Japan, ³Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Recent genome-wide association studies have disclosed several single nucleotide polymorphisms (SNPs) associated with rheumatoid arthritis (RA) susceptibility. Among them, it is reported that the…
Abstract Number: 1187 • 2012 ACR/ARHP Annual Meeting
Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity in Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis: Decreased Inflammation and Disease Improvement with Smoking Cessation?
Catriona Cramb¹, Jeremy Sokolove², Geoffrey M. Thiele³, Gail S. Kerr⁴, Grant W. Cannon⁵, Andreas M. Reimold⁶, Ted R. Mikuls⁷ and William H. Robinson⁸, ¹VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ²Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ³Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Smoking is a major risk factor for rheumatoid arthritis (RA) and has been associated with increased disease severity and lower rates disease remission. We…
Abstract Number: 1188 • 2012 ACR/ARHP Annual Meeting
Fibrinogen Induced Inhibition of Osteoclastogenesis Is Reversed by Citrullination of Fibrinogen by Peptidylarginine Deiminase
Eun Young Lee¹, Ji Soo Kim², Hye Won Kim³, Sung Hae Chang⁴, Jin-Su Song⁵, Hie-Joon Kim⁵, Kyung-Hyun Park-Min⁶, Lionel B. Ivashkiv⁷, Eun Bong Lee⁸ and Yeong Wook Song⁹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Seoul National University College of Medicine, Seoul, South Korea, ³Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, ⁴Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁵Department of Chemistry, Seoul National University, Seoul, South Korea, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁸Seoul National University, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine,, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: There are increasing evidences that autoantibodies and immune complexes (ICs) containing citrullinated fibrinogen are present in rheumatoid arthritis (RA) patients' sera and contribute to…
Abstract Number: 1189 • 2012 ACR/ARHP Annual Meeting
Stromal Cell Markers in the Synovial Tissue of Patients with Early Arthritis and Preclinical Rheumatoid Arthritis
Yuen Kei Choi¹, Olga N. Karpus², Paul Peter Tak³, Jörg Hamann⁴, Christopher D. Buckley⁵, Andrew Filer⁶ and Danielle M. Gerlag⁷, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²1Departments of Experimental Immunology and Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, ³Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Center for Translational Inflammation Research, School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom, ⁶Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁷Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Stromal cells in synovial tissue (ST) of patients with arthritis may have an important role in the initiation and persistence of the inflammatory infiltrate.…
Abstract Number: 1190 • 2012 ACR/ARHP Annual Meeting
Fine Specificity of Anti-Citrullinated Peptide Antibodies Discloses a Heterogeneous Antibody Population in Rheumatoid Arthritis (RA)
John D. Goules, Andreas V. Goules and Athanasios G. Tzioufas, Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are highly specific for the diagnosis of patients with RA. However, the predominant B cell epitopes have not yet been…
Abstract Number: 1191 • 2012 ACR/ARHP Annual Meeting
Nicotinamide Adenine Dinucleotide Phosphate Oxidase Mediated Angiogenesis and Inflammation in the Arthritic Joint
Monika Biniecka¹, Wei Gao², Chin Teck Ng¹, Emese Balogh², Douglas J. Veale² and Ursula Fearon², ¹Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Dublin Academic Medical Centre, St. Vincent's University Hospital, Translation Rheumatology Research Group, Dublin, Ireland
Background/Purpose: To examine the role of Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NADPH oxidase)-derived Reactive Oxygen Species (ROS) and NADPH oxidase-dependent redox signaling events in regulating…
Abstract Number: 1192 • 2012 ACR/ARHP Annual Meeting
IL-21 Regulates B Cell Proliferation and Differentiation in Rheumatoid Arthritis
Lingyun Sun, Rui Liu and Xia Li, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Interleukin (IL)-21 is a member of type I cytokine family. Recent studies have indicated that IL-21 is an important regulator for human B cell…
Abstract Number: 1193 • 2012 ACR/ARHP Annual Meeting
Podoplanin Expression in Rheumatoid Stroma Correlates with Lymphoid Neogenesis and Is Downregulated by Anti-TNF-α Therapy
Regina Faré¹, Elena Izquierdo¹, Manuel J. Del Rey¹, Raquel Celis², Alicia Usategui¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) expand and undergo phenotypic changes that contribute to chronic inflammation and joint destruction. Podoplanin (Pdp) is a…
Abstract Number: 1194 • 2012 ACR/ARHP Annual Meeting
Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations
Elizabeth D. Ferucci¹, Irene Smolik², Tammy L. Choromanski³, David B. Robinson⁴, Marianna M. Newkirk⁵, Marvin J. Fritzler⁶, Antony Rosen⁷, Erika Darrah⁸ and Hani S. El-Gabalawy⁴, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³Alaska Native Tribal Health Consortium, Anchorage, AK, ⁴Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁵Medicine, McGill University Health Centr, Montreal, QC, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸Division of Rheumatology, The Johns Hopkins University, Baltimore, MD
Background/Purpose: Antibodies directed against peptidylarginine deiminase type 4 (PAD-4) are present in a subset of patients with rheumatoid arthritis (RA) and are associated with more…
Abstract Number: 1195 • 2012 ACR/ARHP Annual Meeting
Identification of Follicular Helper T Cells As a Novel Cell Population Potentially Involved in the Pathogenesis of Rheumatoid Arthritis
Sharon Ing¹, Anika Alarakhia¹, Elvira Lindwall¹, Austin Fraser¹, Jerald M. Zakem¹, William E. Davis¹, Tamika A. Webb-Detiege¹, Robert Quinet¹ and Xin Zhang², ¹Rheumatology, Ochsner Medical Center, New Orleans, LA, ²Institute of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…
Abstract Number: 1156 • 2012 ACR/ARHP Annual Meeting
Effectivity of Methotrexate in Therapy of Juvenile Idiopathic Enthesitis-Related Arthritis
Katharina Geitz¹ and Ivan Foeldvari², ¹Pediatric Rheumatology, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ²Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany
Background/Purpose: Juvenile idiopathic enthesitis related arthritis (enthJIA) represents 5 to 10% of children with JIA. Most patients present with peripheral arthritis and enthesitis. Methotrexate was…
Abstract Number: 1157 • 2012 ACR/ARHP Annual Meeting
The Phenotypic Characterization of Juvenile Idiopathic Arthritis in African American Children
Lauren Minor¹, Lori Ponder², Emily G. Ferrell³, Sheila Angeles-Han¹, Christine W. Kennedy⁴, Kelly A. Rouster-Stevens¹, Mina Pichavant¹, Larry B. Vogler³ and Sampath Prahalad¹, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Rheumatology Immunology, Emory Children's Center, Atlanta, GA
Background/Purpose: JIA, a common childhood arthropathy, with an estimated prevalence of 1 in 1000 in children under the age of 16, affects children of all…
Abstract Number: 1158 • 2012 ACR/ARHP Annual Meeting
Development of Cut-off Values for High Disease Activity in Juvenile Idiopathic Arthritis Based On the Juvenile Arthritis Disease Activity Score
Alessandro Consolaro¹, Stefano Lanni¹, Sara Verazza¹, Maria C. Gallo¹, Marta Bertamino¹, Giulia C. Varnier¹, Serena Calandra², Nicolino Ruperto³, Alberto Martini⁴ and Angelo Ravelli⁵, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²University of Genova, Genova, Italy, ³Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, ⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In the last decade, there have been major advances in the management of juvenile idiopathic arthritis (JIA), including the shift towards early aggressive interventions…
Abstract Number: 1159 • 2012 ACR/ARHP Annual Meeting
Reasons and Predictors of Methotrexate Discontinuation in Children with JIA: Results From the Childhood Arthritis Prospective Study (CAPS)
Suzanne Verstappen¹, Lucy R. Wedderburn², H. E. Foster³, Eileen Baildam⁴, Janet Gardner-Medwin⁵, Joyce Davidson⁵, Alice Chieng⁶, Wendy Thomson⁷ and Kimme L. Hyrich⁸, ¹Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ²Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ³Paediatric Rheumatology, Newcastle Hospitals NHS Foundation Trust and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁶Manchester Children's Hospital, Manchester, United Kingdom, ⁷Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ⁸Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is the DMARD of first choice in patients with juvenile idiopathic arthritis (JIA). However, limited data is available on MTX survival, including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].